Levosimendan

Introduction

Mechanisms of Action (Triple Action)

1. Myofilament Calcium Sensitization (Primary Inotropic Mechanism)

• Binds to troponin C (TnC) in the myocardial thin filament in a Ca²⁺-dependent manner
• Stabilizes the Ca²⁺-bound conformation of TnC
• Prolongs actin-myosin cross-bridge interaction, increasing the rate and extent of myocyte contraction
• Because binding is Ca²⁺-dependent, it only works during systole when Ca²⁺ is elevated - this prevents diastolic relaxation abnormalities (unlike other Ca²⁺ sensitizers)
• Does not increase intracellular Ca²⁺ levels, thus avoiding the pro-arrhythmic risks associated with catecholamines or PDE inhibitors

2. PDE III Inhibition

• Potent phosphodiesterase III (PDE III) inhibitor
• Inhibits breakdown of cyclic AMP (cAMP) → increases cAMP → positive inotropy + lusitropy
• Also causes systemic, pulmonary, and coronary vasodilation
• This dual mechanism (Ca²⁺ sensitization + PDE III inhibition) makes its inotropic effect more potent

3. Opening of ATP-dependent K⁺ (K_ATP) Channels

• Opens vascular smooth muscle K_ATP channels → membrane hyperpolarization → vasodilation
• Contributes to peripheral and coronary vasodilation
• May also provide myocardial protection against ischemic injury (ischemic preconditioning-like effect)

Key Pharmacological Properties

Hemodynamic Effects

• Decreases LV filling pressures (PCWP/LVEDP)
• Decreases systemic and pulmonary vascular resistance (afterload reduction)
• Decreases mean arterial pressure (modest)
• Increases cardiac output and cardiac index
• Improves LV-arterial coupling and mechanical efficiency
• Minimal increase in heart rate and myocardial oxygen demand (unlike catecholamines)
• Improves cardiac performance without significant increase in myocardial O₂ demand - a major theoretical advantage over catecholamines

Dosing

• Optional loading dose: 12-24 μg/kg IV over 10 minutes (often omitted to avoid hypotension)
• Maintenance infusion: 0.05-0.1 μg/kg/min, titrated up to 0.2 μg/kg/min
• Infusion typically given over 24 hours; hemodynamic effects persist for several days due to the active metabolite

Clinical Indications

1. Acute decompensated HFrEF with low cardiac output / hypoperfusion, without severe hypotension
2. Perioperative low cardiac output syndrome in cardiac surgery 3Bridge therapy (to LVAD, transplant) in end-stage HF in countries where approved

Major Clinical Trials

REVIVE-II (Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy vs. Placebo)

• ~600 patients with acutely decompensated HF
• Levosimendan: significant improvement in clinical status, serial BNP levels, and hospital length of stay
• BUT: more episodes of hypotension, atrial fibrillation, ventricular ectopy
• Non-significant increase in early deaths at 14-90 days
• Verdict: Symptom benefit without mortality benefit; safety concerns

SURVIVE (Survival of Patients with AHF in Need of Intravenous Inotropic Support)

• 1327 patients with systolic dysfunction and low cardiac output + dyspnea at rest despite diuretics and vasodilators
• Levosimendan vs. dobutamine
• Early reduction in BNP with levosimendan
• No difference in all-cause mortality at 180 days
• Levosimendan: higher incidence of atrial fibrillation but lower incidence of worsening heart failure (WHF)
• Verdict: Non-inferior but not superior to dobutamine

Adverse Effects

Comparison with Other Inotropes

Current Status and Limitations

• Not approved in the United States - lack of compelling data for incremental efficacy vs. conventional inotropic drugs
• Available in Europe and >40 countries for acute HFrEF with low output and hypoperfusion (in absence of severe hypotension)
• Long-term intermittent ambulatory use: did not improve functional capacity or quality of life in advanced HFrEF
• The future role of levosimendan remains uncertain; recent 2024 meta-analyses (Elsaeidy et al., PMID 39261444) confirm modest hemodynamic benefits without clear mortality advantage
• A 2024 network meta-analysis (Zhang et al., PMID 38547524) comparing levosimendan, milrinone, and dobutamine in advanced HF found no single agent definitively superior in mortality

Summary (High-Yield Points)

1. Only available myofilament Ca²⁺ sensitizer
2. Triple mechanism: TnC binding + PDE III inhibition + K_ATP channel opening
3. Ca²⁺-dependent TnC binding = no diastolic dysfunction
4. Active metabolite OR-1896 with t½ >80 hours = prolonged effect
5. Does not increase myocardial O₂ demand (unlike catecholamines)
6. Key trials: REVIVE-II (vs. placebo) and SURVIVE (vs. dobutamine) - no mortality benefit
7. Side effects: hypotension, atrial fibrillation, ventricular ectopy
8. Approved in Europe (>40 countries), NOT in the USA
9. Cannot reduce mortality compared to dobutamine at 180 days (SURVIVE)
10. Still used as bridge therapy and in cardiac surgery in countries where approved